Article: Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleElevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis
AuthorsMok, MY1 2
Cheung, BMY1
Lo, Y
Leung, RYH
Wong, WS
Lau, CS1
KeywordsChemicals And Cas Registry Numbers
Issue Date2007
PublisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.com
CitationJournal Of Rheumatology, 2007, v. 34 n. 11, p. 2224-2229 [How to Cite?]
AbstractObjective. Adrenomedullin (ADM), a vasodilating peptide that possesses antiinflammatory properties, may have a regulatory role in the vascular manifestations of scleroderma (systemic sclerosis, SSc). We examined associapztions between ADM concentrations and vascular manifestations in a cohort of patients with SSc. Methods. Patients were examined for manifestations of severe Raynaud's phenomenon (RP), defined as digital resorption, previous iloprost infusion, and sympathectomy. Doppler echocardiography and lung function tests were performed to detect elevation in pulmonary arterial pressure (PAP; > 35 mm Hg) and interstitial lung disease (ILD). Plasma ADM was measured by radioimmunoassay. Results. Plasma ADM was measured in 62 SSc patients and 21 healthy controls. Elevated PAP was found in 15 (24.2%) SSc patients (mean PAP 46.5 ± 11.2 mm Hg, range 37-74). ADM was not found to be related to age, sex, disease duration, or clinical subset. ADM level was significantly higher (median 13.9 pmol/l) in SSc patients with elevated PAP compared to those with lower PAP (median 7.2 pmol/1) (p = 0.01) and controls (median 7.9 pmol/1) (p = 0.04). ADM level was not different among patients who had elevated PAP with (n = 10) and without concomitant ILD (n = 5) (p = 0.21). SSc patients with severe RP (38.7%; median ADM 11.9 pmol/1) were found not to have different ADM levels compared to controls (p = 0.75). Patients who had both severe RP and elevated PAP were found to have significantly higher ADM levels (median 22.3 pmol/l) than patients who had neither manifestation (median 8.0 pmol/1) (p = 0.006) and those with severe RP alone (median 4.2 pmol/1) (p = 0.006). Conclusion. Elevated ADM was found in SSc patients with increased PAP regardless of concomitant ILD.
ISSN0315-162X
2011 Impact Factor: 3.695
2011 SCImago Journal Rankings: 0.321
ISI Accession Number IDWOS:000250764000018
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorMok, MY
dc.contributor.authorCheung, BMY
dc.contributor.authorLo, Y
dc.contributor.authorLeung, RYH
dc.contributor.authorWong, WS
dc.contributor.authorLau, CS
dc.date.accessioned2010-09-17T10:20:25Z
dc.date.available2010-09-17T10:20:25Z
dc.date.issued2007
dc.description.abstractObjective. Adrenomedullin (ADM), a vasodilating peptide that possesses antiinflammatory properties, may have a regulatory role in the vascular manifestations of scleroderma (systemic sclerosis, SSc). We examined associapztions between ADM concentrations and vascular manifestations in a cohort of patients with SSc. Methods. Patients were examined for manifestations of severe Raynaud's phenomenon (RP), defined as digital resorption, previous iloprost infusion, and sympathectomy. Doppler echocardiography and lung function tests were performed to detect elevation in pulmonary arterial pressure (PAP; > 35 mm Hg) and interstitial lung disease (ILD). Plasma ADM was measured by radioimmunoassay. Results. Plasma ADM was measured in 62 SSc patients and 21 healthy controls. Elevated PAP was found in 15 (24.2%) SSc patients (mean PAP 46.5 ± 11.2 mm Hg, range 37-74). ADM was not found to be related to age, sex, disease duration, or clinical subset. ADM level was significantly higher (median 13.9 pmol/l) in SSc patients with elevated PAP compared to those with lower PAP (median 7.2 pmol/1) (p = 0.01) and controls (median 7.9 pmol/1) (p = 0.04). ADM level was not different among patients who had elevated PAP with (n = 10) and without concomitant ILD (n = 5) (p = 0.21). SSc patients with severe RP (38.7%; median ADM 11.9 pmol/1) were found not to have different ADM levels compared to controls (p = 0.75). Patients who had both severe RP and elevated PAP were found to have significantly higher ADM levels (median 22.3 pmol/l) than patients who had neither manifestation (median 8.0 pmol/1) (p = 0.006) and those with severe RP alone (median 4.2 pmol/1) (p = 0.006). Conclusion. Elevated ADM was found in SSc patients with increased PAP regardless of concomitant ILD.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationJournal Of Rheumatology, 2007, v. 34 n. 11, p. 2224-2229 [How to Cite?]
dc.identifier.epage2229
dc.identifier.hkuros148448
dc.identifier.isiWOS:000250764000018
dc.identifier.issn0315-162X
2011 Impact Factor: 3.695
2011 SCImago Journal Rankings: 0.321
dc.identifier.issue11
dc.identifier.pmid17937467
dc.identifier.scopuseid_2-s2.0-35948991493
dc.identifier.spage2224
dc.identifier.urihttp://hdl.handle.net/10722/91501
dc.identifier.volume34
dc.languageeng
dc.publisherJournal of Rheumatology Publishing Co Ltd. The Journal's web site is located at http://www.jrheum.com
dc.publisher.placeCanada
dc.relation.ispartofJournal of Rheumatology
dc.relation.referencesReferences in Scopus
dc.subject.meshAdrenomedullin - blood
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshCase-Control Studies
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHypertension, Pulmonary - blood - etiology
dc.subject.meshLung Diseases, Interstitial - blood - etiology
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshRaynaud Disease - blood - etiology
dc.subject.meshScleroderma, Systemic - blood - complications - physiopathology
dc.subjectChemicals And Cas Registry Numbers
dc.titleElevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Queen Mary Hospital Hong Kong